NCT05614817: A trial that was reported late by Suzhou Connect Biopharmaceuticals, Ltd.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT05614817 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of CBP-201 Monotherapy in Patients With Moderate-To-Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 31, 2022 |
| Completion date | Aug. 31, 2024 |
| Required reporting date | Aug. 31, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Jan. 9, 2023 |
| Days late | None |